Skip to content
Peptigraph home

5-Amino-1MQ vs AOD-9604: What the Research Shows

5-Amino-1MQ and AOD-9604 side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
NNMT inhibitor (not a peptide)Not FDA approved · research chemical5-Amino-1MQNNMT inhibitor (not a peptide) with no human studies; in diet-induced obese mice, 5-amino-1MQ plus a low-fat diet promoted whole-body adiposity and weight loss.[2]GLP-1 & metabolicHGH fragment analogNot FDA approved · research chemicalAOD-9604Fragment of human growth hormone studied only in animals; in rats, 19 days of oral treatment reduced body-weight gain by over 50%.[8]GLP-1 & metabolic
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider 5-Amino-1MQ if…

  • you are tested in sport and want to avoid a WADA-prohibited substance: AOD-9604 is prohibited by WADA at all times (check 5-amino-1MQ's own status separately)[1]

Consider AOD-9604 if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

What they have in common

  • Only animal or lab studies of 5-amino-1MQ were found (e.g. obese mice): combined with a low-fat diet it promoted marked loss of adiposity and weight[2]
  • Only animal or lab studies of AOD-9604 were found (e.g. rat): Oral AOD9604 for 19 days cut body weight gain by over 50% (15.8 g vs 35.6 g control) in obese Zucker rats.[8]
Neither is FDA approved for any use in people. AOD-9604 is prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 6 of 12 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, Half-life, Evidence strength, Human studies we summarised are the same or both unknown.

Field5-Amino-1MQAOD-9604
ClassNNMT inhibitor (not a peptide)HGH fragment analog
Also called5-amino, 1MQAOD
WADAWADA status unclear5-Amino-1MQ is not named. S4.4 covers AMPK activators, PPAR-delta agonists and Rev-erb agonists by example, and nothing there names an NNMT inhibitor. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.Prohibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times.
Anti-doping detectionNone reportedanti-doping literature, as of 2 Oct 2026
  • AOD9604 can be detected in urine at 50 pg/mL; a stable serum metabolite may lengthen the detection window.PMID 25208511
  • Screening for a stable metabolite may allow a longer detection window (no duration was given).PMID 25208511
Typical study doses
Vial sizes sold5 mg, 10 mg2 mg, 5 mg, 10 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Two different kinds of molecule, both tested only in animals

5-amino-1-methylquinolinium is a small-molecule inhibitor of the enzyme NNMT, a different kind of compound from AOD-9604, a fragment of human growth hormone.[2]

The name AOD9604 reflects its origin: an early rat paper calls it a synthetic lipolytic domain of human growth hormone.[8]

The enzyme work behind 5-amino-1-methylquinolinium screened quinolinium analogues and found a scaffold with NNMT inhibition at about 1 micromolar. This is a test-tube result, not a body-weight result.[13]

What the animal studies measured

In the 5-amino-1-methylquinolinium mouse study, the inhibitor was combined with a low-fat diet in obese mice. The diet switch alone did not restore the same measures.[2]

In rats, oral AOD9604 for 19 days reduced weight gain compared with controls.[8]

The same rat paper found no adverse effect of chronic AOD9604 on insulin sensitivity, unlike intact growth hormone.[8]

In mice lacking the beta-3 adrenergic receptor, long-term AOD9604 failed to change body weight as it did in normal mice.[14]

In a rabbit knee-osteoarthritis model, intra-articular AOD9604 enhanced cartilage regeneration. No such study of 5-amino-1-methylquinolinium is cited here.[7]

A drug profile notes that phase IIa trials of AOD-9604 had begun by February 2002. No published results appear in the abstracts reviewed, and no human study of 5-amino-1-methylquinolinium is cited.[15]

Common questions

Is 5-amino-1MQ or AOD-9604 better for fat loss?

Neither has human data cited here, so neither can be called better. Both have only mouse or rat weight results, and the 5-amino-1MQ result was obtained alongside a diet change.[2]

Is AOD-9604 a peptide?

Yes. It is described as a synthetic lipolytic domain of human growth hormone, whereas 5-amino-1MQ is a small-molecule enzyme inhibitor.[8]

Has AOD-9604 been tested in people?

A drug profile reported phase IIa trials as underway in February 2002. The results are not in the abstracts reviewed.[15]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
  3. 3Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
  4. 4PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
  7. 7Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
  8. 8Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
  9. 9PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("AOD-9604"[tiab] OR AOD9604[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (0 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  12. 12PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  13. 13Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.Journal of medicinal chemistry · 2017PMID 28548833Accessed 2 Oct 2026
  14. 14The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.Endocrinology · 2001PMID 11713213Accessed 2 Oct 2026
  15. 15AOD-9604 Metabolic.Current opinion in investigational drugs (London, England : 2000) · 2004PMID 15134286Accessed 2 Oct 2026

Found an error? Report a correction.